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Abstract
Soluble beta-amyloid (A) oligomers are considered to putatively play a critical role in the early synapse loss and cognitive impairment
observed in Alzheimer’s disease. We previously demonstrated that A oligomers activate cytosolic phospholipase A2 (cPLA2), which
pecifically releases arachidonic acid from membrane phospholipids. We here observed that cPLA2 gene inactivation prevented the
lterations of cognitive abilities and the reduction of hippocampal synaptic markers levels noticed upon a single intracerebroventricular
njection of A oligomers in wild type mice. We further demonstrated that the A oligomer-induced sphingomyelinase activation was
suppressed and that phosphorylation of Akt/protein kinase B (PKB) was preserved in neuronal cells isolated from cPLA2/ mice.
nterestingly, expression of the A precursor protein (APP) was reduced in hippocampus homogenates and neuronal cells from cPLA2/
mice, but the relationship with the resistance of these mice to the A oligomer toxicity requires further investigation. These results therefore
how that cPLA2 plays a key role in the A oligomer-associated neurodegeneration, and as such represents a potential therapeutic target
or the treatment of Alzheimer’s disease.
2012 Elsevier Inc. All rights reserved.
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Alzheimer’s disease (AD) is the principal form of senile
dementia and represents a major health problem in indus-
trialized countries. Its prevalence is increasing and no ef-
fective treatment is currently available. Numerous studies
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versité de Lorraine, 2 avenue de la forêt de Haye, 54500 Vandœuvre-
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0197-4580/$ – see front matter © 2012 Elsevier Inc. All rights reserved.
doi:10.1016/j.neurobiolaging.2011.11.008on animal models and humans support the hypothesis that
synaptic dysfunction and loss induced by the oligomers of
the amyloid-beta peptide (A) are the basis for the cognitive
alterations observed in AD (for review, see Arendt, 2009).
Indeed, the inhibition of long-term potentiation (LTP) and
enhancement of long-term depression (LTD) are considered
to be the first synaptic functional impairments induced by
soluble A oligomers (Lambert et al., 1998; Shankar et al.,
2008; Wang et al., 2002). Alterations of several cellular
metabolic pathways including -amino-3-hydroxy-5-meth-
yl-4-isoxazolepropionic acid (AMPA) receptor trafficking
(Gu et al., 2009) and N-methyl-D-aspartate (NMDA) recep-
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this first event, leading to the reduction of synaptic plasticity
and memory defects. Synapse degeneration results ulti-
mately in the decrease of synaptic density up to 55%, which
has been observed postmortem in the CA1 hippocampal
region of mild AD patients (Arendt, 2009). The preservation
of synaptic function and plasticity can therefore be consid-
ered to be critical during the early prodromal phase of AD
and thus represents an important target for developing po-
tential therapeutics.
The pathways and mechanisms by which A oligomers
induce the early synaptic disruptions are only partially
known and involve several messenger molecules acting as
intracellular and synaptic messengers. Arachidonic acid
(AA; C20:4 6), a long-chain polyunsaturated n-6 fatty acid
s one of these mediators. AA is involved in the regulation
f long-term potentiation and in the retrograde signal gen-
rated by the activation of glutamate AMPA and NMDA
eceptors (Volterra et al., 1992; Williams et al., 1989).
urthermore, AA is converted by different enzymes into
annabinoids and eicosanoids, these derivatives being in-
olved in synaptic signaling and neuroinflammation (Shei-
in et al., 2008). However, AA also exerts its own effects,
ncluding the inhibition of presynaptic and postsynaptic
hannels as well as the formation and recycling of synaptic
esicles (Marza et al., 2008).
AA is released from the sn-2 position of membrane
hospholipids by several phospholipases A2 (PLA2), a large
rotein family that includes secreted as well as cytosolic and
embrane-associated enzymes (Burke and Dennis, 2009).
euronal cells express at least 2 types of phospholipases
2: (1) the calcium-independent membrane-associated en-
zyme (iPLA2) that is thought to be involved in the metab-
lism of docosahexaenoic acid, the major n-3 long-chain
olyunsaturated fatty acid in the brain; and (2) the calcium-
ependent cytosolic enzyme (cPLA2) that displays a strong
selectivity for the AA-containing phospholipids (for review,
see Sun et al., 2010). This latter 85-kDa enzyme, which is
also referred to as GIVA-PLA2 (Schaloske and Dennis,
006), is activated and translocated to membranes after
alcium influx and phosphorylation by mitogen-activated
rotein (MAP) kinases or other kinases (Clark et al., 1995).
ctivation of MAP kinases and perturbation of calcium
omeostasis are well known to be involved in the deleteri-
us effects of A oligomers (Small, 2009; Wang et al.,
2004). We previously reported that soluble A oligomers
aused early calcium-dependent release of AA associated
ith a transient relocalization of cPLA2 to the plasma mem-
rane, suggesting that activation of cPLA2 and subsequent
elease of AA are critical steps for soluble A oligomer-
ediated apoptosis in cortical neurons. We confirmed this
ypothesis by using antisense oligonucleotides and pharma-
ological inhibitors of cPLA2 that abolished AA release and
protected neurons against A-induced apoptosis (Kriem et
l., 2005). Furthermore, we demonstrated that activation ofPLA2 by A oligomers precedes that of sphingomyeli-
nases (SMases) and subsequent production of ceramides
associated with neuronal apoptosis (Malaplate-Armand et
al., 2006). The critical role of cPLA2 in AD is also sup-
ported by the results obtained by Sanchez-Mejia et al.
(2008) on the J20 mice which express mutant human A
precursor protein (APP). These authors showed that breed-
ing J20 with cPLA2/ mice improves the cognitive abili-
ties of the resulting animals compared with the parent line.
Contrary to the iPLA2/ mice whose gene deletion leads to
severe motor dysfunctions (Shinzawa et al., 2008),
cPLA2/ mice display no apparent deficiency of the ner-
vous system and are resistant to the 1-methyl-4-phenyl-
1,2,5,6-tetrahydropyridine neurotoxicity and to ischemic in-
jury (Klivenyi et al., 1998; Tabuchi et al., 2003).
Interestingly, inhibition of cPLA2 in the developing visual
system of zebra fish modifies the morphology of neuronal
tectum arbor and induces faster branch dynamics, while
addition of exogenous AA reverses these effects (Leu and
Schmidt, 2008), suggesting that AA released by activated
cPLA2 can modulate synaptic plasticity.
We previously showed that intracerebroventricular
(ICV) injections of nanomolar levels of A42 oligomers in
wild type (WT) mice rapidly induce short- and long-term
memory deficits, which mimic the early stages of AD (Gar-
cia et al., 2010; Youssef et al., 2008). Because various
interfering pathological mechanisms occur in AD transgenic
murine models such as the one previously used by Sanchez-
Mejia et al. (2008), we applied this model to cPLA2/
mice. In this study, we show that inactivation of cPLA2
gene completely protects synaptic functions and cognitive
abilities against A oligomer toxicity. Furthermore, we pro-
ide evidence that in vivo resistance is mediated by main-
enance of survival pathways in neuronal cells. Finally, we
bserved a reduction of APP expression level in synapto-
ome-enriched fractions from cPLA2/ mice, this effect
eing confirmed in vitro in cPLA2/ neurons cultures and
in WT neuronal cells in which cPLA2 expression was sup-
ressed using pharmacological inhibitors or antisense oli-
onucleotides.
. Methods
.1. Materials
A42 peptides were obtained from Bachem (Weil am
Rhein, Germany). To overcome problems of peptide solu-
bility at high concentrations, fresh peptide stock solutions
were prepared at 5 mg/mL in the disaggregating solvent
hexafluoro-2-propanol, as previously described (Pillot et al.,
1999) and kept frozen at 80 °C. For the incubation of
peptides with neurons, aliquots of peptide stock solution
were quickly dried under nitrogen and directly solubilized at
the experimental concentrations into the culture medium.
Peptide solutions were then applied onto the cells. Before
the use on cell cultures, preparations of A oligomers were
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1123.e19C. Desbène et al. / Neurobiology of Aging 33 (2012) 1123.e17–1123.e29analyzed on 10% polyacrylamide gels. Coomassie-blue
staining revealed A oligomers to be essentially trimers and
tetramers, as previously described (Berman et al., 2008;
Youssef et al., 2008; Supplementary Fig. 1). All chemicals
were purchased from Sigma (St Quentin Fallavier, France)
unless otherwise specified. All media and growth supple-
ments used for cell culture were obtained from Invitrogen
(Illkirch, France). Oligonucleotides were purchased from
Eurogentec (Angers, France).
2.2. Intracerebroventricular injection of soluble A
oligomers
Twelve-week-old male cPLA2/ mice (gift from Dr.
J. Bonventre, Harvard Medical School) and cPLA2/
BALB/c mice (purchased from Janvier Breeding Laborato-
ries, Le Genest St Isle, France) were housed 5 to 6 per cage
with free access to food and water, and were kept in a
constant environment (22  2 °C temperature, 50  5%
humidity, 12-hour light cycle). Soluble A42 oligomers
were prepared as described above as stock solutions at the
concentration of 0.5 mM in sterile 0.1-M phosphate-buff-
ered saline (PBS) (pH 7.4) and aliquots were stored at
20 °C until use. Soluble A42 oligomers (0.5 nmol in 1
L) or vehicle (PBS) were injected into the right ventricle
of anesthetized animals with stereotaxic coordinates from
the bregma being in mm, anteroposterior: 0.22; lateral: 1.0;
and dorsal: 2.5. Injections were made using a 10-L Ham-
lton microsyringe fitted with a 26-gauge needle. Each
roup consisted of 12 animals. Learning and memory ca-
acities were assessed using Y-maze and Morris water maze
ests. The animal facilities and all animal procedures were
pproved by the Animal Care and Veterinary Committee of
eurthe-et-Moselle (Nancy, France).
.3. Y-maze task
Immediate spatial working memory performance was
ssessed by recording spontaneous alternation behavior in a
-maze as previously described (Sarter et al., 1988;
oussef et al., 2008). The Y-maze task was carried out on
ay 4 after soluble A oligomers administration. The maze
as made of opaque plexiglas and arms were 40 cm long,
6 cm high, 9 cm wide, and positioned at equal angles. Mice
ere placed at the end of one arm and allowed to move
reely through the maze during a 5-minute session. The
eries of arm entries were recorded visually and arm entry
as considered to be completed when the hind paws of the
ouse were completely placed in the arm. Alternation was
efined as successive entries into the 3 arms on overlapping
riplet sets. The percentage alternation was calculated as the
atio of actual (total alternations) to possible alternations
defined as the total number of arm entries minus 2), mul-
iplied by 100..4. Morris water maze task
The Morris water maze task was performed as previously
escribed (Morris, 1984). The experimental apparatus con-
isted of a circular water tank (diameter  80 cm; height 
0 cm) containing water at 22 °C, 25 cm deep and rendered
paque by adding an aqueous acrylic emulsion. A platform
diameter  10 cm) was submerged 1 cm below the water
urface and placed at the midpoint of 1 quadrant. The pool
as placed in a test room homogenously illuminated with a
ight intensity of 100 lux and containing various prominent
isual cues. The swimming paths of the animals were re-
orded using a video tracking system.
On Days 3 and 4 after injection, navigation to a visible
latform was carried out before place-navigation in order to
valuate visual and motor abilities of the animals. Mice
ere submitted to 4 trials per day with 2 trials in the
orning and 2 trials in the afternoon, and with an intertrial
nterval of at least 45 minutes. There was no extra maze cue
n the room. The platform position and starting points were
andomly distributed over all 4 quadrants of the pool. Mice
hat failed to find the platform after 60 seconds were man-
ally guided to its location.
Memory-acquisition trials (training) were performed 4
imes daily on Days 7–11 after injection of soluble A
oligomers to reach a steady state of escape latency. The
mice were allowed to swim freely for 60 seconds, were left
for an additional 30 seconds period on the hidden platform,
and were then returned to the home cage during the intertrial
interval. The intertrial intervals between 4 trials were 45
minutes. Start positions, set at each limit between quadrants,
were randomly selected for each animal. In each trial, the
time required to escape onto the hidden platform was re-
corded. Mice failing to find the platform within 60 seconds
were manually placed on the platform for 10 seconds at the
end of the trial.
Memory-retention tests (probe trials) were performed on
Day 14, i.e., 3 days after the last training session. The
platform was removed and each mouse was allowed to a
free 60-second swim. The number of crossings over the
previous location of the platform and the time spent in each
of the 4 quadrants were measured by replay using a video
recorder.
2.5. Cell cultures and treatments
Primary cultures of cortical neurons were prepared from
mouse or rat fetuses dissected on embryonic Days 16–17
according to Bouillot et al. (1996) and Pillot et al. (1999).
riefly, dissociated cells were plated at 1.5  105 cells per
cm2 for mouse cells or at 5  104 cells per cm2 for rat cells
in plastic dishes precoated with polyornithine (1.5 mg/mL).
Cells were cultured in serum free Dulbecco’s modified
Eagle’s/F-12 medium and supplemented with hormones,
proteins, salts and 0.1% (wt/vol) ovalbumin. Cultures were
maintained at 35 °C in a humidified 6% CO2 atmosphere.
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1123.e20 C. Desbène et al. / Neurobiology of Aging 33 (2012) 1123.e17–1123.e29Such culture conditions promote neuronal cell selection and
prevent astroglial proliferation. After 6–7 days in vitro
(DIV), the cellular population was determined to be at least
96% neuronal by immunostaining with neuron-specific
markers. All experiments were performed on 6–7 DIV
neurons. Cells were treated with 1 or 5 M soluble oligom-
ers of A42 for the indicated times or with 1 or 2 M of the
cPLA2 inhibitor methoxy arachidonyl fluorophosphonate
(MAFP) for 24 hours. Two sets of cPLA2 sense and anti-
ense oligonucleotides were designed and used as previ-
usly described (Kriem et al., 2005).
.6. Neuronal viability and monitoring of apoptosis
Cell viability was assessed using the 3-(4,5-dimethylthi-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as
reviously described (Pillot et al., 1999; Sponne et al.,
004). Cell nuclei were visualized using 4,6-diamidino-2-
henylindole (DAPI) staining (Sponne et al., 2004). To
valuate the percentage of apoptotic cells, 10 independent
elds of microscope were counted (approximately 400
ells) in 3 separate experiments with 3 determinations each
Kriem et al., 2005).
.7. Measurement of sphingomyelinase activities
Cells (2  106) were washed twice with PBS, pH 7.4,
nd lysed in 0.1% Triton X-100 for 10 minutes at 4 °C. The
ysates were sonicated for 30 seconds in ice-cold bath, and
rotein concentrations were determined by bicinchoninic
cid (BCA) Protein Assay Kit (Pierce, Illkirch, France).
cidic and neutral sphingomyelinase (A-SMase and N-
Mase) activities were measured at pH 4.5 and 7.4, respec-
ively, with the fluorescent substrate 6-hexadecanoylamino-
-methylumbelliferyl phosphocholine (HMU-P-Chol; Mosc-
rdam Substrates, Oegstgeest, the Netherlands) as previ-
usly described (Kilkus et al., 2003). Twenty-five micro-
ram proteins, buffered either in 150 mM sodium acetate
olution, containing 0.1% Triton X-100, 0.2% 3-[(3-
holamidopropyl) dimethylammonio]-1-propanesulfonate
CHAPS) (pH 4.5) (A-SMase activity), or in PBS, 0.1%
riton X-100, 0.2% CHAPS, 0.5 mM MgCl2 (pH 7.4)
N-SMase activity), were incubated for up to 10 hours with
.6 mM HMU-P-Chol. The fluorescence was monitored at
70-nm excitation and 460-nm emission using a Fluostar
icroplate reader (BMG-Labtechnologies, Champigny
/Marne, France). SMases activities were calculated from
he slope of the intrinsic fluorescence versus time graph,
tandardized per microgram of proteins and expressed as a
ercentage of control values.
.8. Immunoblot analyses
Primary cultures of cortical neurons treated under differ-
nt conditions as described in the figures legends were
ashed with ice-cold PBS. Cells were then solubilized in a
5 mM Tris-HCl (pH 7.4) lysis buffer containing 150 mM
aCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 1%wt/vol) sodium deoxycholate, 1% (vol/vol) nonidet P-40,
.1% (wt/vol) sodium dodecyl sulfate (SDS) and protease
nhibitors (Complete, Roche, Meylan, France). After homog-
nization, collected cells were then lysed by using 3 cycles of
reezing and thawing and finally centrifuged at 10,000g at 4 °C
or 10 minutes. Protein concentration in the supernatant was
etermined by BCA Protein Assay Kit (Pierce). Samples were
ixed with an equal volume of 2 Laemmli buffer, and then
enatured by heating the mixture at 100 °C for 5 minutes.
Synaptosomal membrane-enriched fractions were pre-
ared as previously described (Keller et al., 1997). Briefly,
rain regions were dissected and rapidly homogenized in
ce-cold 10 mM Tris buffer (pH 7.4) containing 0.32 mM
ucrose, 2 mM EDTA, 10 g/mL sodium orthovanadate and
rotease inhibitors. The homogenate was spun at 800g for
5 minutes to remove nuclei and cell debris. The resulting
upernatant was then centrifuged at 12,000g for 20 minutes
nd a second pellet was collected. This fraction, which is
nriched in synaptosomes but also contains other compo-
ents such as mitochondria, was used to evaluate the ex-
ression levels of the synaptic proteins.
Samples (cell extracts or synaptosome-enriched frac-
ions) were then subjected to SDS polyacrylamide gel elec-
rophoresis (PAGE) and immunoblotting. The following
ntibodies were used: actin (1:1000 dilution; C-11 antibody;
anta Cruz, Heidelberg, Germany); Akt and P-Akt (S473)
1:1000 dilution; Cell Signaling, Saint Quentin en Yvelines,
rance); postsynaptic density protein 95 (PSD95; 1:500
ilution; Cell Signaling); -tubulin (1:1000 dilution; Santa
ruz); synaptotagmin (1:1000 dilution; Calbiochem, Lyon,
rance); synaptophysin (1:500 dilution; Chemicon, Mol-
heim, France), glial fibrillary acidic protein (GFAP) (1:
000 dilution; Millipore, Molsheim, France), ionized cal-
ium binding adapter molecule 1 (Iba1; 1:1000 dilution;
bcam, Paris, France), APP (1:1000 dilution; 22C11 anti-
ody; Millipore). Immunoblots were probed with the cor-
esponding horseradish peroxidase-conjugated secondary
ntibodies (1:2000 dilution; Cell Signaling) and detected
sing the enhanced chemiluminescence protocol (ECL Kit;
mersham Biotech, Orsay, France). The Quantity One soft-
are (version 4.5), associated with the VersaDoc Imag-
ng System (Model 1000; Bio-Rad, Marnes-la-Coquette,
rance), was used to quantify the protein levels.
.9. Statistical analysis
StatView computer software (version 5.0, SAS Institute,
ary, NC) was used for the statistical analysis. Data were
btained from 3 to 5 separate experiments with 6 determi-
ations each. Differences between control and treated
roups were analyzed using Student t test. Multiple pairwise
omparisons among the groups were performed using anal-
sis of variance (ANOVA) followed by a Scheffe’s post hoc
est (p  0.05 indicates significant differences between
groups). For behavioral analysis, statistical comparisons
were made by the Student t test and one-way analysis of
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1123.e21C. Desbène et al. / Neurobiology of Aging 33 (2012) 1123.e17–1123.e29variance was carried out and followed by Fisher’s post hoc
test. All reported values are expressed as the mean  stan-
dard error of the mean (SEM).
3. Results
3.1. cPLA2/ mice are fully resistant to soluble A
oligomer-induced cognitive alterations
To determine whether cPLA2 contributed to soluble A
oligomer-dependent cognitive impairment in vivo, we com-
pared the memory and learning performances of cPLA2/
and cPLA2/ (WT) mice. WT mice or cPLA2/ mice
were injected with 500 pmol soluble A42 oligomers or
ehicle (n  12 per group) as previously described (Garcia
t al., 2010; Youssef et al., 2008). The cognitive perfor-
ances of mice were then monitored by Y-maze and Morris
ater-maze tests reflecting immediate spatial working
emory performance, as well as learning and long-term
emory capabilities, respectively.
Fig. 1. cPLA2/ mice are resistant to soluble beta-amyloid (A) oli-
omer-induced short-term memory impairment. The Y-maze tests were
erformed on Day 4 after intracerebroventricular (ICV) injection of soluble
42 oligomers (500 pmol) or vehicle into cPLA2/ or wild type (WT)
mice. Control mice were injected with vehicle (phosphate buffered saline
[PBS]). (A) Spontaneous alteration behavior and the number of arm entries
were measured during 5-minute sessions to evaluate spatial memory. (B)
The number of arm entries did not differ among the different groups of
mice. Locomotor, exploratory, visual, and motivational activities did not
differ among groups. Data are presented as mean  standard error of the
mean (SEM) (n  12).As expected, WT mice injected with soluble A oligom-
ers displayed significantly impaired spatial working mem-
ory (16% decrease in alternation behavior), while no alter-
ation of short-term memory abilities were observed for the
cPLA2/ mice after injection of A oligomers (Fig. 1A).
he number of arm entries did not change significantly
mong all the experimental groups (Fig. 1B), indicating that
he observed changes were not due to exploratory, locomo-
or, visual, or motivational effects between WT and
PLA2/ mice.
In the Morris water maze, injection of A oligomers did
not suppress but dramatically reduced the learning abilities
of the WT mice (12–20 seconds longer escape latencies
along the 5 training days) (Fig. 2A). Such a partial loss—
but not suppression—of learning abilities has been previ-
ously reported in other works using ICV injections of var-
ious forms of A peptides (A1–42, A1–40, A3–42,
A25–35) (Kim et al., 2010; Pan et al., 2010; Tsukuda et al.,
2009; Youssef et al., 2008). The probe tests indicated that
Fig. 2. cPLA2/ mice are resistant to soluble beta-amyloid (A) oli-
omer-induced learning and long-term memory impairment. The Morris
ater-maze tests were performed from Day 7 to Day 14 after intracere-
roventricular (ICV) injection of soluble A42 oligomers (500 pmol) or
vehicle into cPLA2/ or wild type (WT) mice. Control mice were injected
with vehicle (phosphate buffered saline [PBS]). (A) The training trials were
carried out on Days 7–11 after A injection. Escape latency in training was
measured and represented as the mean of a block of 4 trials per day. (B)
The probe trial was carried out on Day 14 after A42 injection. The time
equired for the first crossing over the platform site was recorded. All mice
howed normal swimming performance (data not shown). Data are pre-
ented as mean  standard error of the mean (SEM) (n  12).the long-term memory abilities of these mice were strongly
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In contrast, in cPLA2/ mice, the A-induced decrease in
cognitive performance was not observed (Fig. 2A and B).
Similar distances were achieved by the mice of the various
experimental groups, indicating the absence of effect on lo-
comotion, visual abilities, or motivation (data not shown).
Therefore, the results of this cognitive test indicate that the
inactivation of cPLA2 gene rendered the mice fully resistant to
A-induced alterations of learning and long-term memory.
.2. cPLA2/ mice are fully resistant to soluble A
oligomer-induced synaptic impairments
Increasing evidence suggests that soluble A oligomers
dversely affect synaptic function, which leads to cognitive
ailure associated with AD (Arendt, 2009; Gu et al., 2009).
e next examined whether cPLA2 influenced soluble A
oligomer-induced synaptic degeneration in vivo. Because
the hippocampus plays a critical role in memory and is the
first brain region affected in AD, we examined the expres-
sion of synaptic proteins in hippocampal neurosynapto-
some-enriched fractions prepared from WT and cPLA2/
mice that were ICV-injected with A42 oligomers or vehi-
cle. In WT mice, both pre- and postsynaptic proteins were
affected at Day 14 after A oligomer injection. Synaptotag-
Fig. 3. cPLA2/ mice are resistant to soluble beta-amyloid (A) oli-
omer-induced synaptic impairments. After the behavioral analysis was
ompleted, mice were sacrificed at Day 14 after intracerebroventricular
ICV) injection and synaptosome-enriched fractions were prepared from
ippocampus. (A) Representative immunoblots of synaptic proteins from
PLA2/ and wild type (WT) mice after A or vehicle ICV injection are
hown. (B) Densitometric analyses of synaptic proteins immunoblots from
42- and vehicle-exposed mice were normalized to actin. Data are ex-
pressed as % of control (vehicle injections) and are represented as mean 
standard error of the mean (SEM) of 3 separate immunoblots.in, synaptophysin, and PSD95 were dramatically de-reased in WT mice upon A oligomers exposure (Fig. 3A).
This was confirmed by quantitative analyses of the immu-
noblots (Fig. 3B). In contrast, the levels of all synaptic
proteins were maintained in hippocampal synaptosomal
fractions obtained from A-treated cPLA2/ mice (Fig.
A and B). Thus, the preservation of cognitive functions in
PLA2/mice after ICV administration of A oligomers was
accompanied by the absence of decline in hippocampal syn-
aptic proteins levels, indicating that inactivation of cPLA2 gene
preserved synaptic integrity against AD-like stress.
Fig. 4. Intracerebroventricular injection of beta-amyloid (A) oligomers is
ot associated with neuroinflammation. Wild type (WT) mice were sacri-
ced 6, 24, and 48 hours after intracerebroventricular (ICV) injection of
oluble A42 oligomers (500 pmol) or vehicle and homogenates were
repared from cortex and hippocampus. (A) Immunoblots of the astroglial
lial fibrillary acidic protein (GFAP) and microglial ionized calcium bind-
ng adapter molecule 1 (Iba1) markers are shown. (B) Densitometric
nalyses of Iba1 immunoblots from vehicle- and A42-exposed mice nor-
malized to tubulin were carried out. Data are represented as mean 
standard error of the mean (SEM) of 2 separate immunoblots. (C) Densi-
tometric analyses of GFAP immunoblots from vehicle- and A42-exposed
mice after normalization to tubulin were performed. Data are represented
as mean  SEM of 2 separate immunoblots.
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associated with an increase in neuro-inflammation
markers
AA released through the activation of cPLA2 can be
onverted in a series of proinflammatory mediators which
an lead to neuroinflammation and glial proliferation. To
etermine whether A injection was followed by inflam-
matory processes and glial activation, we examined the
expression levels of GFAP and Iba1 as astroglial and mi-
croglial markers, respectively (Romero-Sandoval et al.,
2008) in A- and vehicle-injected WT mice. We observed
a weak and variable increase in hippocampal Iba1 levels 6
and 24 hours after vehicle ICV injection compared with the
levels observed after A administration (Fig. 4A and B).
Iba1 expression was decreased in hippocampus 48 hours
after vehicle injection compared with 6 and 24 hours. How-
ever, after A ICV administration, it remained at the same
level throughout the times studied (Fig. 4A and B). By
contrast, no significant variation of Iba1 expression levels
was observed in the cortex between 6 and 48 hours after
vehicle or A injections (Fig. 4A and B). Similarly, no
change in GFAP levels was observed in both hippocampus
and cortex in the same period of time in all groups studied
excluding astroglial activation (Fig. 4A–C). These results
suggest that inflammatory processes do not significantly
contribute to A-induced behavioral and synaptic impair-
ments in our ICV injection model.
3.4. cPLA2/ neurons are resistant to soluble A
oligomer-induced neurotoxic and apoptotic effects
To determine whether the resistance of cPLA2/ mice
to A oligomer-induced cognitive and synaptic impair-
ents could be associated with resistance of neuronal cells,
e next investigated the effects of the inactivation of cPLA2
gene on the soluble A-induced neurotoxic and apoptotic
effects in vitro. As expected from our previous reports
(Florent et al., 2006; Garcia et al., 2010; Kriem et al., 2005;
Malaplate-Armand et al., 2006), the incubation of cortical
neurons of WT mice with 1 or 5 M A42 oligomers for 24
hours resulted in a 40%–50% decrease in cell viability (Fig.
5A), whereas 1 M A42 induced a 5-fold increase in
poptotic nuclei number, as compared with untreated WT
eurons (Fig. 5B). Interestingly, cPLA2/ cortical neurons
ere fully resistant to these soluble A effects (Fig. 5A and
B). Moreover, cortical neurons of WT mice incubated with
1 M A42 for 6 hours (i.e., prior to apoptosis measurement
at 24-hour incubation time) exhibited a 65% reduction of
the synaptic PSD95 protein expression level. In contrast,
PSD95 level was preserved in cPLA2/ cortical neurons in
he presence of 1 M A42 oligomers (Fig. 5C and D).
We have previously identified SMases as potential
downstream actors in the A-activated cPLA2 proapoptotic
cascade (Malaplate-Armand et al., 2006). Here, the incuba-
tion of cortical WT neurons with 1 M A42 oligomers for A3 hours led to a marked increase in both A-SMase and
N-SMase activities (3- and 2.5-fold, respectively). In
cPLA2/ neurons, however, this activation of N- and A-
Mases in response to A42 exposure was not observed
Fig. 6A and B).
Alterations of the prosurvival Akt signaling pathway
ave emerged as an important feature in AD-associated
euronal death (Lee et al., 2009). In WT cortical neurons,
Fig. 5. Primary cortical neurons from cPLA2/ mice are resistant to
oluble beta-amyloid (A) oligomer-induced cytotoxic and apoptotic ef-
ects. Primary cultures of cortical neurons from wild type (WT) and
PLA2/ mice were incubated for 24 hours with soluble A42 oligomers.
A) Cell survival was monitored by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
iphenyltetrazolium bromide (MTT) assay. Data are normalized to the
ffect of vehicle, designated as 100%. (B) Apoptotic nuclei were visualized
sing 4,6-diamidino-2-phenylindole (DAPI) staining (data not shown) and
uantified from 10 individual fields per coverslip. For each set of experi-
ents, data are represented as the mean  standard error of the mean
(SEM) of 3 independent experiments with 4 determinations each. (C)
Postsynaptic density protein 95 (PSD95) expression levels were measured
in lysates of primary cultures of cortical neurons from WT and cPLA2/
mice which were incubated for 6 hours with 1 M A42 oligomers or
ehicle. A representative immunoblot is shown for 2 independent immu-
oblot analyses. (D) Densitometric analyses of PSD95 immunoblots on
ysates of cortical neurons were performed. Data are expressed as % of the
SD95/tubulin ratio obtained in presence of A42 oligomers normalized to
that of vehicle-treated cells (of the same genotype), and are represented as
mean  SEM of 2 separate immunoblots.kt phosphorylation was drastically reduced by 80%
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oligomers during 3 hours, while it was not altered in the
cPLA2/ cells compared with the untreated controls
(Fig. 6C and D).
Taken together, these data indicate that cPLA2 repre-
sents an important and crucial mediator of A oligomer-
Fig. 6. Activation of sphingomyelinases (SMases) is suppressed and Akt
pathway is preserved in cPLA2/ neurons in presence of soluble beta-
myloid (A) oligomers. Treatment with 1 M A42 oligomers for 6 hours
was performed on primary cultures of cortical neurons. Acidic SMase (A)
and Neutral SMase (B) activities were monitored by measuring the relative
increase in fluorescence due to the cleavage of fluorogenic substrate in the
presence of cell extracts. Data are represented as the mean standard error
f the mean (SEM) of 3 independent experiments with 4 determinations
ach, normalized to the effect of vehicle, designated as 100%. (C) Analyses
f the phosphorylation levels of Akt after A42 exposure were performed
n immunoblots of protein extracts isolated from wild type (WT) or
PLA2/ neurons at 7 days in vitro (DIV). These neurons were exposed
o 1 M A42 soluble oligomers or vehicle for 3 hours. A representative
immunoblot is shown for 3 independent immunoblot analyses. (D) Densi-
tometric analyses of phospho-Akt (P-Akt) and total Akt immunoblots on
lysates of primary cultures of neuronal cells were performed. Data are
expressed as p-Akt/total Akt ratio obtained in presence of A42 oligomers
normalized to vehicle-treated cells of the same genotype. Quantifications
are shown as mean  SEM of 3 separate immunoblots.induced apoptotic cascade and the suppression of itsactivity leads to a full resistance to the neurotoxic effects
of A oligomers.
3.5. Effects of gene inactivation and pharmacological
inhibition of cPLA2 on the level of neuronal APP
expression
Because previous works reported that nonspecific inhib-
itors or activators of the AA/PLA2 cascade modulate APP
etabolism and hydrolysis (Emmerling et al., 1993; Kinou-
hi et al., 1995), we investigated the relationship between
PLA2 expression and activity on one hand and APP ex-
ression on the other hand. We first examined the influence
f cPLA2 gene inactivation on APP expression and we
Fig. 7. Cytosolic phospholipase A2 (cPLA2) inhibition is associated with
a lower level of neuronal beta-amyloid (A) precursor protein (APP)
full-length protein. Immunoblot analyses of full-length APP (A) in
protein extracts from cPLA2/ and wild type (WT) mice primary
cultures of cortical neurons, (B) in homogenates from cPLA2/ and
T mice hippocampus, (C) in protein extracts from rat primary cultures
f cortical neurons treated for 24 hours with the specific pharmacolog-
cal cPLA2 inhibitor methoxy arachidonyl fluorophosphonate (MAFP),
and (D) in protein extracts from rat primary cultures of cortical neurons
treated for 48 hours with 4 M antisense oligonucleotides against
PLA2 (antisense oligonucleotide AS1 and AS2) and control sense oli-
gonucleotides (S1 and S2). Representative densitometric analyses of
immunoblots of APP normalized to tubulin were carried out. Data are
shown as mean  standard error of the mean (SEM) of 3 separate
immunoblots.
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tracts of neurons and hippocampal homogenates from
cPLA2/ mice than in those from WT mice (Fig. 7A and
B). We further observed that inhibition of cPLA2 activity in
rat cortical neurons by using 1 or 2 M of the pharmaco-
logical cPLA2 inhibitor MAFP for 24 hours decreased APP
levels by 25% and 70%, respectively (Fig. 7C). We had
previously demonstrated that the antisense oligonucleotides
AS1 and AS2 targeting cPLA2 protect neuronal cells against
 oligomer neurotoxicity (Kriem et al., 2005). Incubation
of neuronal cells with 4 M of AS1 and AS2 for 48 hours
ed to a 2-fold decrease in APP levels (Fig. 7D). Whether
nd how the reduction of APP levels and the resistance to
 oligomer neurotoxicity are mechanistically related, re-
ains to be elucidated.
. Discussion
In this study, we provide new evidence that cPLA2 is an
early and crucial mediator of A oligomer-induced cogni-
tive deficit associated with synaptic impairment. We found
that inactivation of the cPLA2 gene renders mice completely
esistant to the behavioral alterations in learning as well as
n short- and long-term memory that occur following a
ingle ICV injection of soluble A peptide. Accordingly,
ippocampal synaptic integrity is maintained in cPLA2/
mice. In addition, the activation of the proapoptotic path-
ways induced by the A oligomers is suppressed in neuro-
nal cells of cPLA2/ mice. The influence of cPLA2 in AD
pathogenesis has been explored in chronic AD models such
as transgenic mice models or in postmortem human brains.
Indeed, its levels of messenger RNA (mRNA) and protein
are increased in the hippocampal CA1 area of AD patients
(Colangelo et al., 2002; Stephenson et al., 1996). cPLA2 has
also been proposed to be a key enzyme in several patho-
logical processes in the nervous system such as ischemia/
reperfusion injuries (Tabuchi et al., 2003) and experimental
autoimmune encephalomyelitis, a model of multiple sclero-
sis (Marusic et al., 2005).
The studies on the AD mechanisms and on putative
therapeutic strategies have largely been based on the use of
transgenic mice expressing human APP and presenilin
genes. In these models, large amounts of A peptide are
produced early, leading to its accumulation in amyloid
plaques and generating complex pathological phenomena
such as glial activation, inflammation, and oxidative stress.
Such being the case, the respective contributions of the
various forms of A peptide, including the intraneuronal
forms, extracellular monomers, oligomers, or amyloid fi-
brils are difficult to discriminate. For example, increased
levels of proinflammatory mediators were measured in
transgenic AD mice models. Sanchez-Mejia et al. (2008), in
a study using transgenic hAPP J20 mice, suggested that
cPLA2 gene inactivation inhibits the AD neurodegenerative
rocess by reducing the production of proinflammatory ei-osanoids. In this study, we used a more relevant model
imicking the early stages of sporadic AD in which behav-
oral and synaptic impairments are induced upon acute ex-
osure to small amounts of extracellular A oligomers
Garcia et al., 2010; Youssef et al., 2008). The preparations
f synthetic A42 oligomers used contained predominantly
rimers and tetramers similar to those prepared from syn-
hetic batches or produced in recombinant cell systems
Berman et al., 2008; Supplementary Fig. 1). This approach
llows the determination of the neurotoxic transduction
athways induced by the A oligomers in order to identify
therapeutic targets aimed towards inhibiting or decreasing
the sensitivity of neural cells to these oligomers. Evaluation
of protein levels of astroglial or microglial markers indi-
cated no significative neuroinflammation in this model.
Dysfunction of synapses and reduction of plasticity are
typical and early function-related events in the AD patho-
genesis (Selkoe, 2002). Several papers reported that synap-
tic loss is initiated by alterations in glutamate receptors and
other synaptic proteins involved in trafficking and endocy-
tosis (Parameshwaran et al., 2008). It is worth noting here
that a single injection of A oligomers could induce drastic
reductions of the levels of several synaptic markers, synap-
totagmin, synaptophysin, and PSD95, and that this effect
was abolished by cPLA2 gene inactivation. Interestingly,
anchez-Mejia et al. (2008) reported that 10 M of A42
oligomers transiently increased surface levels of the AMPA
receptor GluR1 and GluR2 subunits on cultured neurons,
and the use of arachidonyl trifluoromethyl ketone (AA-
COCF3), another pharmacological inhibitor of cPLA2 sup-
pressed this effect. Despite that the concentration of A42
oligomers used was 10-fold higher than in our neuronal
cultures, these results together support the notion that
cPLA2 plays a critical role in A oligomer-induced neu-
osynaptotoxicity. The presynaptic proteins synaptophysin
nd synaptotagmin are involved in the formation of soluble
-ethylmaleimide-sensitive factor attachment protein re-
eptor (SNARE) complexes with several other partners such
s syntaxin-1 and Munc18. AA stabilizes interactions be-
ween Munc18, syntaxin-1 and synaptosomal-associated
rotein, 25 kDa (SNAP25), thus favoring exocytosis of
eurotransmitters (Connell et al., 2007; Latham et al.,
007). Increase in free AA released by cPLA2 in response to
 oligomers could therefore be involved in synaptic dys-
functions. Moreover, a fraction of cPLA2 binds to Golgi
apparatus in response to calcium and its activity is increased
by Ser505 phosphorylation (Tucker et al., 2009). Previous
eports showed that cPLA2 activity modifies the transport of
everal proteins between Golgi vesicles and plasma mem-
ranes in nonneuronal cell types (Choukroun et al., 2000;
egan-Klapisz et al., 2009). Taking this into account along
ith the role of AA in Munc18-syntaxin interactions (Con-
ell et al., 2007) and the influence of cPLA2 on membrane
organization and lipid vesicles formation (Gubern et al.,
2008), it is tempting to speculate that A-activated cPLA2
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various lipid compartments.
Besides synaptotoxicity, neuronal apoptosis is another
hallmark of AD. A oligomers generate a proapoptotic
pathway through SMase activation and ceramide produc-
tion (Alessenko et al., 2004; Malaplate-Armand et al.,
2006). We previously demonstrated that cPLA2 activa-
ion occurs upstream to that of SMases by using phar-
acological inhibitors and antisense oligonucleotides
Malaplate-Armand et al., 2006). We confirm here the
ink between cPLA2 and SMase activation in A-induced
neuronal apoptosis by showing that cPLA2 gene inacti-
ation completely precludes activation of both A- and
-SMases by A oligomers. Furthermore, Akt/protein
inase B (PKB) survival pathway is also maintained in
euronal cells derived from cPLA2/ mice in the pres-
nce of A oligomers, contrary to those derived from WT
ice. Indeed, it has been demonstrated that AA released
y cPLA2 is a negative regulator of Akt/PKB activation
by growth factors and insulin in striated muscle cells
(Haq et al., 2003). We therefore show that the in vivo
resistance to A-induced alterations of cognitive abilities
nd synaptic protein levels is associated with the in vitro
esistance of neuronal cells to the proapoptotic and anti-
urvival effects of A oligomers.
Activation of Akt/PKB and PI3-kinase also modulates
PP trafficking and lysosomal degradation (Shineman et
l., 2009). Interestingly, we observed a reduction of APP
evels in hippocampal homogenates and primary cultured
euronal cells from cPLA2/ mice. Moreover, this effect
was mimicked in rat primary neuronal cultures in the pres-
ence of cPLA2 inhibitors or antisense oligonucleotides. This
s in contrast to the study of Sanchez-Meija et al. (2008),
ho did not observe any variation of the human APP level
or A production in their transgenic J20 mice. Whether
ouse endogenous APP expression levels were modified
as not indicated in their study. Culicchia et al. (2008)
ecently described simultaneous overexpression of cPLA2
and APP in several human glioblastoma cell lines, suggest-
ing a link between these 2 proteins. After its maturation and
transportation from endoplasmic reticulum and Golgi appa-
ratus to synaptic membranes, APP is rapidly internalized
and subsequently trafficked through endosomes back to the
cell surface or degraded in the lysosomes (Thinakaran and
Koo, 2008). Since cPLA2 modifies the transport of several
proteins between Golgi vesicles and plasma membranes in
nonneuronal cells as we discussed above (Choukroun et al.,
2000; Regan-Klapisz et al., 2009), cPLA2 might regulate
APP trafficking and metabolism similar to other synaptic
proteins into various lipid compartments. Besides its role in
A peptide generation, APP protein is required for synaptic
plasticity and other neuronal functions (Dawson et al., 1999;
Priller et al., 2006). Moreover A oligomers bind to the
cognate A extracellular domain of APP and generate a G
rotein-dependent intracellular signaling pathway throughPP dimerization (Shaked et al., 2006, 2009). These data
uggest that modifications of APP expression and/or pro-
essing could be involved in the cPLA2 inhibition-mediated
protection against A oligomers neurotoxicity.
Recent studies have been devoted toward the design of
antibodies (Hillen et al., 2010), peptides (Esteras-Chopo et
al., 2008), flavonoids (Thapa et al., 2011), or other pharma-
ceutical compounds (Zhao et al., 2009) to block A peptide
oligomerization, but the in vivo efficiency of such a strategy
requires extensive knowledge of the oligomerization pro-
cess and the toxicity of the various oligomeric forms. Other
studies have focused on the functional interactions between
A peptide and glutamate receptors (Decker et al., 2010b;
Hu et al., 2009; Texidó et al., 2011; Zhao et al., 2010) or
have attempted to reinforce neuronal defenses through the
neurotrophic effects of growth factors or membrane lipids
such as docosahexaenoic acid (Ma et al., 2009). Many
NMDA receptor modulators have been characterized and
are potential therapeutics for Alzheimer’s disease. How-
ever, clinical assays are required to demonstrate their ther-
apeutic efficiency. Neurotrophic compounds are interesting
from a preventive point of view, and epidemiological stud-
ies should be used to determine the target populations. Other
approaches have focused on the oxidative stress generated
by A peptide, but the specificity and efficiency are uncer-
tain because oxidative stress is found in many diseases and
is not the only pathological mechanism in AD. Finally,
many studies identified intracellular mediators of the A
peptide neurotoxic effects. These intracellular targets in-
clude membrane-phospholipid remodeling enzymes such as
synaptojanin and phospholipase D (Berman et al., 2008;
Oliveira et al., 2010) or signaling proteins such as fyn
kinase, glycogen synthase kinase-3, cyclin-dependent ki-
nase-5 (Crews and Masliah, 2010). Some inhibitors of these
putative therapeutic targets have been proposed because of
their potential specificity.
In conclusion, our study provides both in vitro and in
vivo evidence for the crucial role that cPLA2 plays in A
oligomer-induced neurodegeneration, synaptotoxicity and
memory impairments at early stages of AD. The mecha-
nisms by which cPLA2 gene inactivation disrupts A oli-
omers in vitro and in vivo neurotoxicity remain yet to be
elineated, but our results led us to propose cPLA2 as a
potentially useful therapeutic target for developing disease
modifying therapies for AD.
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